Sanofi’s bispecific scores in respiratory diseases but fails in eczema

Data ReadoutMixedlunsekimigNeutral

AI Analysis

Summary

Sanofi's bispecific antibody lunsekimig met primary endpoints in asthma and CRSwNP but failed to meet the primary endpoint in eczema. The mixed trial results present both positive and negative implications for the program's development pathway.

Clinical Trial Data

Outcome Details

Met primary endpoints in asthma and CRSwNP; missed primary endpoint in eczema

Importance:7/10

Sentiment:

-0.10

Phase 3 databispecific antibodyrespiratory diseasedermatologymixed results

Related Companies

$SNYNF

Read the original article

Published by Clinical Trials Arena on April 7, 2026 4:36 PM

Read Original